How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) issued its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.68.

When did ContraVir Pharmaceuticals' stock split?

Shares of ContraVir Pharmaceuticals reverse split on the morning of Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 28th 2018. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of ContraVir Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraVir Pharmaceuticals investors own include Ayala Pharmaceuticals (ADXS) , Alliqua Biomedical (ALQA) , Synergy Pharmaceuticals (SGYP) , Palatin Technologies (PTN) , LadRx (CYTR) , Madrigal Pharmaceuticals (MDGL) , Biopharmx (BPMX) , Heat Biologics (HTBX) and Ritter Pharmaceuticals (RTTR) .

NASDAQ:CTRV

ContraVir Pharmaceuticals (CTRV) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CTRV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.04
▼
$2.21
50-Day Range: $2.53
▼
$3.58
52-Week Range: $3.52
▼
$91.00

Volume: 27,949 shs
Average Volume: 432,822 shs
Market Capitalization: $1.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get ContraVir Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About ContraVir Pharmaceuticals Stock (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

CTRV Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive CTRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraVir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/13/2016
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CTRV
CUSIP: N/A
CIK: 1583771
Web: www.contravir.com
Phone: 732-902-4000
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,450,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -4,810.77%
Return on Assets: -130.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.55
Quick Ratio: 0.55

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.80 per share
Price / Book: 2.66

Miscellaneous

Outstanding Shares: 800,000
Free Float: N/A
Market Cap: $1.70 million
Optionable: Not Optionable
Beta: 1.16

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Robert T. Foster BSc (Pharm) (Age 61)
Pharm.D., Ph.D., CEO, Pres, Chief Scientific Officer & Director
Dr. John Z. Sullivan-Bolyai (Age 71)
Part-Time Consultant
Mr. John T. Cavan (Age 61)
Chief Financial Officer
Sharen Pyatetskaya
Director of Investor Relations

Key Competitors

View All Competitors

CTRV Stock Analysis - Frequently Asked Questions

How were ContraVir Pharmaceuticals' earnings last quarter?: ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) issued its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.68.
When did ContraVir Pharmaceuticals' stock split?: Shares of ContraVir Pharmaceuticals reverse split on the morning of Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 28th 2018. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What other stocks do shareholders of ContraVir Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ContraVir Pharmaceuticals investors own include Ayala Pharmaceuticals (ADXS), Alliqua Biomedical (ALQA), Synergy Pharmaceuticals (SGYP), Palatin Technologies (PTN), LadRx (CYTR), Madrigal Pharmaceuticals (MDGL), Biopharmx (BPMX), Heat Biologics (HTBX) and Ritter Pharmaceuticals (RTTR).

This page (NASDAQ:CTRV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ContraVir Pharmaceuticals (CTRV) Stock Price, News & Analysis

About ContraVir Pharmaceuticals Stock (NASDAQ:CTRV)

CTRV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CTRV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info